JP2018537501A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018537501A5 JP2018537501A5 JP2018531479A JP2018531479A JP2018537501A5 JP 2018537501 A5 JP2018537501 A5 JP 2018537501A5 JP 2018531479 A JP2018531479 A JP 2018531479A JP 2018531479 A JP2018531479 A JP 2018531479A JP 2018537501 A5 JP2018537501 A5 JP 2018537501A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- disease
- compound according
- ring
- sulfur
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 239000001301 oxygen Substances 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 239000011593 sulfur Substances 0.000 claims 4
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 claims 3
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 208000025487 periodic fever syndrome Diseases 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 208000007815 Acquired Hyperostosis Syndrome Diseases 0.000 claims 1
- 208000026326 Adult-onset Still disease Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000005024 Castleman disease Diseases 0.000 claims 1
- 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 241001481833 Coryphaena hippurus Species 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 claims 1
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 201000004854 SAPHO syndrome Diseases 0.000 claims 1
- 201000010848 Schnitzler Syndrome Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000001931 aliphatic group Chemical group 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 208000002849 chondrocalcinosis Diseases 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021019843A JP7317878B2 (ja) | 2015-12-17 | 2021-02-10 | 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用 |
| JP2023117597A JP2023126574A (ja) | 2015-12-17 | 2023-07-19 | 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562268765P | 2015-12-17 | 2015-12-17 | |
| US62/268,765 | 2015-12-17 | ||
| US201662353603P | 2016-06-23 | 2016-06-23 | |
| US62/353,603 | 2016-06-23 | ||
| PCT/US2016/067112 WO2017106607A1 (en) | 2015-12-17 | 2016-12-16 | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021019843A Division JP7317878B2 (ja) | 2015-12-17 | 2021-02-10 | 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018537501A JP2018537501A (ja) | 2018-12-20 |
| JP2018537501A5 true JP2018537501A5 (OSRAM) | 2020-01-30 |
| JP6882299B2 JP6882299B2 (ja) | 2021-06-02 |
Family
ID=58191545
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018531479A Active JP6882299B2 (ja) | 2015-12-17 | 2016-12-16 | 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用 |
| JP2021019843A Active JP7317878B2 (ja) | 2015-12-17 | 2021-02-10 | 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用 |
| JP2023117597A Pending JP2023126574A (ja) | 2015-12-17 | 2023-07-19 | 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021019843A Active JP7317878B2 (ja) | 2015-12-17 | 2021-02-10 | 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用 |
| JP2023117597A Pending JP2023126574A (ja) | 2015-12-17 | 2023-07-19 | 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用 |
Country Status (29)
| Country | Link |
|---|---|
| US (7) | US10399957B2 (OSRAM) |
| EP (3) | EP3889145B1 (OSRAM) |
| JP (3) | JP6882299B2 (OSRAM) |
| KR (2) | KR102787063B1 (OSRAM) |
| CN (2) | CN108699032B (OSRAM) |
| AU (3) | AU2016371014B2 (OSRAM) |
| CA (1) | CA3005766A1 (OSRAM) |
| CL (1) | CL2018001624A1 (OSRAM) |
| DK (1) | DK3889145T3 (OSRAM) |
| ES (2) | ES2883285T3 (OSRAM) |
| FI (1) | FI3889145T3 (OSRAM) |
| HR (1) | HRP20240355T1 (OSRAM) |
| HU (1) | HUE066591T2 (OSRAM) |
| IL (4) | IL279751B (OSRAM) |
| LT (1) | LT3889145T (OSRAM) |
| MX (2) | MX385424B (OSRAM) |
| MY (2) | MY210123A (OSRAM) |
| NZ (1) | NZ742476A (OSRAM) |
| PH (1) | PH12018501068A1 (OSRAM) |
| PL (1) | PL3889145T3 (OSRAM) |
| PT (1) | PT3889145T (OSRAM) |
| RS (1) | RS65319B1 (OSRAM) |
| SG (2) | SG10202001146PA (OSRAM) |
| SI (1) | SI3889145T1 (OSRAM) |
| SM (1) | SMT202400141T1 (OSRAM) |
| TW (3) | TWI804003B (OSRAM) |
| UA (1) | UA124802C2 (OSRAM) |
| WO (1) | WO2017106607A1 (OSRAM) |
| ZA (1) | ZA201803367B (OSRAM) |
Families Citing this family (109)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3889145B1 (en) * | 2015-12-17 | 2024-02-21 | Merck Patent GmbH | 8-cyano-5-piperidino-quinolines as tlr7/8 antagonists and their uses for treating immune disorders |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| PL3484865T3 (pl) | 2016-07-14 | 2023-01-09 | Crinetics Pharmaceuticals, Inc. | Modulatory somatostatyny i ich zastosowania |
| US10947214B2 (en) | 2016-08-08 | 2021-03-16 | Merck Patent Gmbh | TLR7/8 antagonists and uses thereof |
| KR20230010826A (ko) | 2016-10-14 | 2023-01-19 | 프리시젼 바이오사이언시스 인코포레이티드 | B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제 |
| US11370794B2 (en) * | 2016-11-11 | 2022-06-28 | Dynavax Technologies Corporation | Toll-like receptor antagonist compounds and methods of use |
| EP3655401B1 (en) * | 2017-07-18 | 2023-09-06 | Merck Patent GmbH | Tlr7/8 antagonists and uses thereof |
| CN117659025A (zh) * | 2017-10-30 | 2024-03-08 | 科罗拉多州立大学董事会法人团体 | Toll样受体8（tlr8）特异性拮抗剂及其制备方法和用途 |
| CA3086172A1 (en) * | 2017-12-19 | 2019-06-27 | Merck Patent Gmbh | Tlr7/8 antagonists and uses thereof |
| CN111511754B (zh) | 2017-12-20 | 2023-09-12 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸 |
| US10966999B2 (en) | 2017-12-20 | 2021-04-06 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| EP3752505B1 (en) | 2018-02-12 | 2023-01-11 | F. Hoffmann-La Roche AG | Novel sulfone compounds and derivatives for the treatment and prophylaxis of virus infection |
| CA3091142C (en) | 2018-02-26 | 2023-04-11 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
| US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
| AU2019280728A1 (en) * | 2018-06-05 | 2020-11-12 | F. Hoffmann-La Roche Ag | Tetrahydro-1 H-pyrazino[2,1 -ajisoindolylquinoline compounds for the treatment of autoimmune disease |
| TW202016105A (zh) | 2018-06-12 | 2020-05-01 | 瑞士商赫孚孟拉羅股份公司 | 用於治療自體免疫疾病的新穎雜芳基雜環基化合物 |
| EP3807271A1 (en) * | 2018-06-13 | 2021-04-21 | F. Hoffmann-La Roche AG | Pyridinyl heterocyclyl compounds for the treatment of autoimmune disease |
| WO2020006018A1 (en) | 2018-06-27 | 2020-01-02 | Bristol-Myers Squibb Company | Substituted naphthyridinone compounds useful as t cell activators |
| MX2020013373A (es) | 2018-06-27 | 2021-03-09 | Bristol Myers Squibb Co | Compuestos de naftiridinona utiles como activadores de celulas t. |
| CA3103987C (en) * | 2018-07-06 | 2023-08-01 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
| JPWO2020017569A1 (ja) * | 2018-07-17 | 2021-12-02 | 日本ケミファ株式会社 | Ｔ型カルシウムチャネル阻害剤 |
| EP3826724B1 (en) * | 2018-07-23 | 2022-10-05 | F. Hoffmann-La Roche AG | Novel piperazine compounds for the treatment of autoimmune disease |
| JP7491900B2 (ja) * | 2018-07-31 | 2024-05-28 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｔｌｒ７／８アンタゴニストおよびそれらの使用 |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| US20210323977A1 (en) | 2018-08-28 | 2021-10-21 | Hoffmann-La Roche Inc. | Pyrrolidinyl amide compounds for the treatment of autoimmune disease |
| EP3847169A1 (en) | 2018-09-04 | 2021-07-14 | F. Hoffmann-La Roche AG | Benzothiazole compounds for the treatment of autoimmune diseases |
| EP3847173B1 (en) | 2018-09-06 | 2023-04-12 | F. Hoffmann-La Roche AG | Novel pyrazolopyridine compounds for the treatment of autoimmune disease |
| JP2022502353A (ja) * | 2018-09-06 | 2022-01-11 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 自己免疫疾患の処置のための新規の環状アミジン化合物 |
| JP2022501326A (ja) * | 2018-09-07 | 2022-01-06 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 自己免疫疾患の治療のための新規ピロリジンアミン化合物 |
| US20220112187A1 (en) * | 2018-09-11 | 2022-04-14 | Hoffmann-La Roche Inc. | Pyrazolopyridine amine compounds for the treatment of autoimmune disease |
| EP3623369B1 (en) | 2018-09-12 | 2023-10-25 | F. Hoffmann-La Roche AG | Novel morpholinyl amine compounds for the treatment of autoimmune disease |
| JP2022501401A (ja) * | 2018-09-27 | 2022-01-06 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 自己免疫疾患の治療のためのヘテロシクリル化合物 |
| CN109516925B (zh) * | 2018-10-31 | 2021-07-16 | 陕西慧康生物科技有限责任公司 | 一种谷氨酸-1-甲酯-5-叔丁酯的合成方法 |
| MX2021005047A (es) | 2018-10-31 | 2021-09-08 | Gilead Sciences Inc | Compuestos de 6-azabenzimidazol sustituidos como inhibidores de hpk1. |
| CN117105933A (zh) | 2018-10-31 | 2023-11-24 | 吉利德科学公司 | 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物 |
| EP3877388B1 (en) * | 2018-11-09 | 2023-07-26 | F. Hoffmann-La Roche AG | 5-[6-[[3-(4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl)azetidin-1-yl]methyl]morpholin-4-yl]quinoline-8-carbonitrile derivatives and similar compounds as tlr7-9 antagonists for treating systemic lupus erythematosus |
| CN109369571A (zh) * | 2018-12-04 | 2019-02-22 | 无锡市赛乐新材料科技有限公司 | 一种含氟取代的7-溴-4-醛基苯并噻二唑及其合成方法 |
| US11008303B2 (en) | 2019-01-30 | 2021-05-18 | Insilico Medicine Ip Limited | TLR 9 inhibitors |
| US11807622B2 (en) | 2019-01-30 | 2023-11-07 | Insilico Medicine Ip Limited | TLR 9 inhibitors |
| US10689360B1 (en) * | 2019-01-30 | 2020-06-23 | Insilico Medicine Ip Limited | TLR inhibitors |
| CN113454086B (zh) | 2019-02-07 | 2025-03-14 | 百济神州有限公司 | 作为tlr7激动剂的咪唑并[2,1-f][1,2,4]三嗪-4-胺衍生物 |
| DK3934757T3 (da) | 2019-03-07 | 2023-04-17 | Inst Of Organic Chemistry And Biochemistry Ascr V V I | 2'3'-cykliske dinukleotider og prodrugs deraf |
| US11766447B2 (en) | 2019-03-07 | 2023-09-26 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| AU2020231115B2 (en) | 2019-03-07 | 2025-02-20 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| JP2022081710A (ja) * | 2019-03-29 | 2022-06-01 | ユーティアイ リミテッド パートナーシップ | 関節リウマチを治療するためのｔ型カルシウムチャネル阻害剤の使用 |
| JPWO2020203609A1 (OSRAM) * | 2019-03-29 | 2020-10-08 | ||
| MA55594A (fr) * | 2019-04-09 | 2022-02-16 | Hoffmann La Roche | Composés hexahydro-1h-pyrazino[1,2-a]pyrazine pour le traitement d'une maladie auto-immune |
| TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
| CN112094224B (zh) * | 2019-06-18 | 2022-08-26 | 浙江医药股份有限公司新昌制药厂 | 一种带保护基的3-取代-5-氨基哌啶的制备方法 |
| US20220296619A1 (en) | 2019-08-19 | 2022-09-22 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| CN112430208A (zh) * | 2019-08-26 | 2021-03-02 | 东莞市东阳光仿制药研发有限公司 | 一种pf-06651600中间体的制备方法 |
| AR119821A1 (es) | 2019-08-28 | 2022-01-12 | Bristol Myers Squibb Co | Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t |
| US20220363665A1 (en) * | 2019-09-10 | 2022-11-17 | Hoffmann-La Roche Inc. | Quinoline compounds for the treatment of autoimmune disease |
| JP2022547729A (ja) | 2019-09-16 | 2022-11-15 | エフ．ホフマン－ラ ロシュ アーゲー | 自己免疫疾患を治療するためのピペリジニルアミン化合物 |
| EP4458975A3 (en) | 2019-09-30 | 2025-02-12 | Gilead Sciences, Inc. | Hbv vaccines and methods treating hbv |
| KR20220087497A (ko) | 2019-10-18 | 2022-06-24 | 더 리전츠 오브 더 유니버시티 오브 캘리포니아 | 병원성 혈관을 표적화하기 위한 화합물 및 방법 |
| WO2021084022A1 (en) * | 2019-10-31 | 2021-05-06 | F. Hoffmann-La Roche Ag | Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease |
| JP7707163B2 (ja) * | 2019-11-12 | 2025-07-14 | エフ． ホフマン－ラ ロシュ アーゲー | 自己免疫疾患の処置のためのヒドロピラジノ［１，２－ｂ］イソキノリン化合物 |
| CN114728976B (zh) * | 2019-11-19 | 2024-08-16 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的氢-1H-吡咯并[1,2-a]吡嗪化合物 |
| JP2023502238A (ja) * | 2019-11-19 | 2023-01-23 | エフ．ホフマン－ラ ロシュ アーゲー | 自己免疫疾患の処置のためのトリアザトリサイクル化合物 |
| US12421252B2 (en) | 2019-11-20 | 2025-09-23 | Hoffmann-La Roche Inc. | Spiro (isobenzofuranazetidine) compounds for the treatment of autoimmune disease |
| JP7676391B2 (ja) * | 2019-11-26 | 2025-05-14 | エフ． ホフマン－ラ ロシュ アーゲー | 自己免疫疾患の処置のための１，８－ナフチリジン－２－オン化合物 |
| KR20220122637A (ko) | 2019-11-28 | 2022-09-02 | 바이엘 악티엔게젤샤프트 | 면역 활성화를 위한 dgk알파 억제제로서의 치환된 아미노퀴놀론 |
| US12421229B2 (en) | 2019-12-03 | 2025-09-23 | Hoffmann-La Roche Inc. | Hydropyrido[1,2-α]pyrazine compounds for the treatment of autoimmune disease |
| EP4069729B1 (en) | 2019-12-06 | 2025-01-22 | Precision BioSciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
| US12479841B2 (en) | 2019-12-18 | 2025-11-25 | Intervet, Inc. | Anthelmintic compounds comprising azaindoles structure |
| JP7712274B2 (ja) | 2019-12-23 | 2025-07-23 | ブリストル－マイヤーズ スクイブ カンパニー | Ｔ細胞アクティベーターとして有用な置換ピペラジン誘導体 |
| KR20220119454A (ko) | 2019-12-23 | 2022-08-29 | 브리스톨-마이어스 스큅 컴퍼니 | T 세포 활성화제로서 유용한 치환된 퀴나졸리닐 화합물 |
| AR120823A1 (es) | 2019-12-23 | 2022-03-23 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos útiles como activadores de células t |
| AR121620A1 (es) | 2020-03-20 | 2022-06-22 | Gilead Sciences Inc | Profármacos de nucleósidos 4-c-sustituidos-2-halo-2-deoxiadenosina y métodos de preparación y uso de los mismos |
| IL298124A (en) * | 2020-05-14 | 2023-01-01 | Merck Healthcare Kgaa | Tlr7/8 antagonists for the treatment of corona virus infection |
| JP2023531414A (ja) * | 2020-06-15 | 2023-07-24 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｔｌｒ７／８アンタゴニスト及びその使用 |
| US20240350492A1 (en) | 2020-07-10 | 2024-10-24 | Ting Therapeutics Llc | Methods for the Prevention and Treatment of Hearing Loss |
| TW202214632A (zh) * | 2020-07-27 | 2022-04-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 吲哚稠環類衍生物、其製備方法及其在醫藥上的應用 |
| WO2022028389A1 (zh) * | 2020-08-03 | 2022-02-10 | 江苏恒瑞医药股份有限公司 | 稠三环类衍生物、其制备方法及其在医药上的应用 |
| CN114057754B (zh) * | 2020-08-07 | 2023-05-16 | 江苏恒瑞医药股份有限公司 | 含氮桥环类衍生物、其制备方法及其在医药上的应用 |
| SMT202500315T1 (it) | 2020-09-09 | 2025-11-10 | Crinetics Pharmaceuticals Inc | Formulazioni di un modulatore della somatostatina |
| WO2022067462A1 (en) * | 2020-09-29 | 2022-04-07 | Beigene (Beijing) Co., Ltd. | Process for preparing inhibitors of kras g12c |
| AU2021385752A1 (en) | 2020-11-26 | 2023-06-29 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Fused tricyclic compound, preparation method therefor and application thereof in medicine |
| KR102513463B1 (ko) * | 2020-11-26 | 2023-03-29 | 주식회사 에스앤케이테라퓨틱스 | 엔도솜 톨-유사 수용체를 제어하는 신규 소분자 화합물 및 이를 이용한 자가면역질환 치료제 |
| CN115109032B (zh) * | 2021-03-18 | 2023-09-05 | 成都百裕制药股份有限公司 | 喹啉衍生物及其在医药上的应用 |
| US11661431B2 (en) | 2021-04-16 | 2023-05-30 | Gilead Sciences, Inc. | Thienopyrrole compounds |
| AU2022274607A1 (en) | 2021-05-13 | 2023-11-16 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
| JP7686086B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリエルコール（ｄｉａｃｙｌｇｌｙｅｒｃｏｌ）キナーゼ調節化合物 |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CN117957234A (zh) | 2021-09-10 | 2024-04-30 | 吉利德科学公司 | 噻吩并吡咯化合物 |
| CN115160296B (zh) * | 2022-08-08 | 2024-05-28 | 西安市第五医院 | 一种n-取代喹啉-4-胺类化合物及其制备、药物组合物和应用 |
| CN115650881B (zh) * | 2022-09-06 | 2025-01-17 | 浙江医药股份有限公司新昌制药厂 | 一种利用微反应器合成喹诺酮类化合物中间体的工艺方法 |
| WO2024153063A1 (zh) | 2023-01-18 | 2024-07-25 | 苏州科睿思制药有限公司 | Enpatoran的晶型及其制备方法和用途 |
| WO2025201636A1 (en) | 2023-03-31 | 2025-10-02 | Syngenta Crop Protection Ag | Pesticidally-active 2,2-dihalocyclopropyl compounds |
| WO2025214612A1 (en) | 2023-04-14 | 2025-10-16 | Syngenta Crop Protection Ag | Pesticidally-active 2,2-dihalocyclopropyl compounds |
| WO2025032195A1 (en) | 2023-08-09 | 2025-02-13 | Merck Patent Gmbh | Crystalline form h1 of 5-((3r,55)-3-amino-5- trifluoromethyl-piperidin-1-yl)-quinoline-8-carbonitrile hemihydrate |
| WO2025032190A1 (en) | 2023-08-09 | 2025-02-13 | Merck Patent Gmbh | Crystalline form a1 of 5-((3r,55)-3-amino-5- trifluoromethyl-piperidin-1-yl)-quinoline-8-carbonitrile hcl |
| WO2025032197A1 (en) | 2023-08-09 | 2025-02-13 | Merck Patent Gmbh | Crystalline form of 5-((3r,5s)-3-amino-5-trifluoromethyl-piperidin-1-yl)-quinoline-8-carbonitrile |
| WO2025160132A1 (en) * | 2024-01-23 | 2025-07-31 | Maplight Therapeutics, Inc. | Gpr6 inverse agonists |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
| WO2025240243A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1020252A (en) * | 1911-04-26 | 1912-03-12 | Arthur H Bell | Brooder. |
| US1016829A (en) * | 1911-05-19 | 1912-02-06 | Abraham Hurwitz | Device for setting pallet-jewels. |
| US1227293A (en) * | 1914-04-10 | 1917-05-22 | Charles H Morison | Safety-catch for cuff-buttons. |
| US1271680A (en) * | 1918-01-15 | 1918-07-09 | Emanuel W Dunn | Heater. |
| US1367747A (en) * | 1919-05-07 | 1921-02-08 | George B Keplinger | Bath-brush |
| DE812911C (de) | 1945-03-12 | 1951-09-06 | Rhone Poulenc Sa | Verfahren zur Herstellung von neuen substituierten Derivaten des Piperidins |
| CH578535A5 (en) | 1973-05-11 | 1976-08-13 | Ciba Geigy Ag | Quinoline-3-carboxylic acid derivs - with e.g. analgesic, antinociceptive, antiinflammatory and antiallergic props |
| US4933447A (en) * | 1987-09-24 | 1990-06-12 | Ss Pharmaceutical Co., Ltd. | Quinoline derivatives |
| FR2798656B1 (fr) | 1999-09-17 | 2004-12-17 | Aventis Pharma Sa | Derives de la quinolyl propyl piperidine, leur preparation et les compositions qui les contiennent |
| CN1585768A (zh) | 2001-11-14 | 2005-02-23 | 默克专利股份有限公司 | 作为精神药物的吡唑衍生物 |
| GB0206033D0 (en) | 2002-03-14 | 2002-04-24 | Pfizer Ltd | Compounds useful in therapy |
| WO2003105850A1 (en) | 2002-06-18 | 2003-12-24 | Abbott Laboratories | 2-aminoquinolines as melanin concentrating hormone receptor antagonists |
| WO2004016576A1 (ja) | 2002-08-12 | 2004-02-26 | Takeda Pharmaceutical Company Limited | 縮合ベンゼン誘導体および用途 |
| BR0316164A (pt) | 2002-11-12 | 2005-09-27 | Pfizer Prod Inc | Derivados de quinolina |
| GB0227240D0 (en) | 2002-11-21 | 2002-12-31 | Glaxo Group Ltd | Compounds |
| GB0229281D0 (en) * | 2002-12-16 | 2003-01-22 | Novartis Ag | Organic compounds |
| US20050124625A1 (en) * | 2003-10-21 | 2005-06-09 | Salvati Mark E. | Piperazine derivatives and their use as modulators of nuclear hormone receptor function |
| JPWO2005087749A1 (ja) | 2004-03-15 | 2007-08-09 | 協和醗酵工業株式会社 | ２−アミノキナゾリン誘導体 |
| US20060211752A1 (en) | 2004-03-16 | 2006-09-21 | Kohn Leonard D | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression |
| WO2005115361A2 (en) | 2004-05-17 | 2005-12-08 | Acadia Pharmaceuticals Inc. | Androgen receptor modulators and method of treating disease using the same |
| US20070004679A1 (en) | 2004-05-17 | 2007-01-04 | Nathalie Schlienger | Androgen receptor modulators and methods of treating disease using the same |
| US20080081817A1 (en) | 2004-07-23 | 2008-04-03 | Tanabe Seiyaku Co., Ltd. | Nitrogenous Fused Bicyclic Compound |
| CN101023083A (zh) * | 2004-07-23 | 2007-08-22 | 田边制药株式会社 | 含氮的稠合双环化合物 |
| JP2006056882A (ja) * | 2004-07-23 | 2006-03-02 | Tanabe Seiyaku Co Ltd | ピラゾロピリミジン化合物 |
| US20090264415A2 (en) | 2004-12-30 | 2009-10-22 | Steven De Jonghe | Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment |
| GB0510810D0 (en) | 2005-05-26 | 2005-06-29 | Novartis Ag | Organic compounds |
| GB0526042D0 (en) | 2005-12-21 | 2006-02-01 | Syngenta Participations Ag | Chemical compounds |
| US20090042857A1 (en) | 2006-02-20 | 2009-02-12 | Masuo Yamaoka | Novel Pharmaceutical |
| AU2007287430B2 (en) | 2006-08-23 | 2011-07-21 | Kudos Pharmaceuticals Limited | 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors |
| EP1903038A1 (de) * | 2006-09-07 | 2008-03-26 | Bayer Schering Pharma Aktiengesellschaft | N-(1-Hetaryl-piperidin-4-yl)-(het)arylamide als EP2-Rezeptor Modulatoren |
| EP2094686A1 (en) | 2006-09-26 | 2009-09-02 | Glaxo Group Limited | 5-{2-[4-(2-methyl-5-quinolinyl)-l-piperidinyl]ethyl} quinolinone derivatives as 5ht1a receptor modulators for treating sexual dysfunction, cognition impairement, psychotic disorders, anxiety, depression, etc. |
| CL2008001002A1 (es) | 2007-04-11 | 2008-10-17 | Actelion Pharmaceuticals Ltd | Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana. |
| KR101608702B1 (ko) | 2007-06-05 | 2016-04-04 | 사노피 | 디(헤테로)아릴사이클로헥산 유도체, 이들의 제조방법, 이들의 용도 및 이들을 포함하는 약제학적 조성물 |
| US20110294789A1 (en) | 2008-05-12 | 2011-12-01 | Amnestix, Inc. | Compounds for rho kinase inhibition and for improving learning and memory |
| EP2320895A2 (en) | 2008-07-03 | 2011-05-18 | Exelixis, Inc. | Cdk modulators |
| MX2011002367A (es) * | 2008-09-02 | 2011-04-04 | Novartis Ag | Inhibidores de cinasa biciclicos. |
| SG171809A1 (en) * | 2008-12-01 | 2011-07-28 | Merck Patent Gmbh | 2, 5-diamino-substituted pyrido [4, 3-d] pyrimidines as autotaxin inhibitors against cancer |
| EP2396328A2 (en) | 2009-02-11 | 2011-12-21 | The Regents of The University of California | Toll-like receptor modulators and treatment of diseases |
| ES2432070T3 (es) * | 2009-02-24 | 2013-11-29 | Respiratorius Ab | Diazaheteroarilos broncodilatadores novedosos |
| WO2011009015A1 (en) | 2009-07-16 | 2011-01-20 | Mallinckrodt Inc. | (+) - morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof |
| US20120214803A1 (en) * | 2011-02-18 | 2012-08-23 | Vifor (International) Ag | Novel Sulfonaminoquinoline Hepcidin Antagonists |
| WO2013060881A1 (en) | 2011-10-27 | 2013-05-02 | Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg | Pyridopyrimidines and their therapeutic use |
| WO2014086453A1 (en) | 2012-12-07 | 2014-06-12 | Merck Patent Gmbh | Azaheterobicyclic compounds |
| NZ754039A (en) | 2013-06-26 | 2021-06-25 | Abbvie Inc | Primary carboxamides as btk inhibitors |
| TWI529171B (zh) * | 2013-07-29 | 2016-04-11 | 赫孚孟拉羅股份公司 | １，７－萘啶衍生物 |
| AU2014308616B2 (en) | 2013-08-23 | 2018-12-06 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| RS59911B1 (sr) | 2013-10-14 | 2020-03-31 | Eisai R&D Man Co Ltd | Selektivno supstituisana jedinjenja hinolina |
| CA2920791C (en) * | 2013-10-14 | 2021-11-16 | Eisai R&D Management Co., Ltd. | Selectively substituted quinoline compounds |
| CN104557913B (zh) | 2013-10-28 | 2017-02-08 | 上海汇伦生命科技有限公司 | 吡啶并嘧啶类化合物，其制备方法和用途 |
| JP2016540013A (ja) * | 2013-12-13 | 2016-12-22 | 武田薬品工業株式会社 | Ｔｌｒ阻害剤としてのピロロ［３，２−ｃ］ピリジン誘導体 |
| EP3083618B1 (en) | 2013-12-17 | 2018-02-21 | Pfizer Inc | Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors |
| WO2015120111A2 (en) | 2014-02-05 | 2015-08-13 | Stereokem, Inc. (Usa) | Expedient synthesis of sitagliptin |
| CN104945377A (zh) | 2014-03-24 | 2015-09-30 | 南京明德新药研发股份有限公司 | 作为smo抑制剂的喹啉衍生物 |
| NZ724691A (en) | 2014-03-24 | 2018-02-23 | Guangdong Zhongsheng Pharmaceutical Co Ltd | Quinoline derivatives as smo inhibitors |
| ES2804101T3 (es) | 2014-04-22 | 2021-02-03 | Hoffmann La Roche | Compuestos de 4-amino-imidazoquinolina |
| GB201411236D0 (en) | 2014-06-25 | 2014-08-06 | Takeda Pharmaceutical | Novel compounds |
| KR102602947B1 (ko) | 2014-11-03 | 2023-11-16 | 아이오메트 파마 엘티디 | 제약 화합물 |
| UY36390A (es) | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen |
| WO2016087593A1 (en) | 2014-12-05 | 2016-06-09 | Syngenta Participations Ag | Novel fungicidal quinolinylamidines |
| MA41169A (fr) | 2014-12-17 | 2017-10-24 | Acraf | Composés antibactériens à large spectre d'activité |
| JP2018525345A (ja) | 2015-07-01 | 2018-09-06 | ノースウェスタン ユニバーシティ | 置換キナゾリン化合物及びグルコセレブロシダーゼ活性の調節のためのその使用 |
| WO2017031427A1 (en) | 2015-08-19 | 2017-02-23 | 3-V Biosciences, Inc. | COMPOUNDS AND METHODS FOR INHIBITING mTOR |
| EP3889145B1 (en) | 2015-12-17 | 2024-02-21 | Merck Patent GmbH | 8-cyano-5-piperidino-quinolines as tlr7/8 antagonists and their uses for treating immune disorders |
| US10947214B2 (en) | 2016-08-08 | 2021-03-16 | Merck Patent Gmbh | TLR7/8 antagonists and uses thereof |
| EP3655401B1 (en) | 2017-07-18 | 2023-09-06 | Merck Patent GmbH | Tlr7/8 antagonists and uses thereof |
| CA3086172A1 (en) | 2017-12-19 | 2019-06-27 | Merck Patent Gmbh | Tlr7/8 antagonists and uses thereof |
| JP7491900B2 (ja) * | 2018-07-31 | 2024-05-28 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｔｌｒ７／８アンタゴニストおよびそれらの使用 |
-
2016
- 2016-12-16 EP EP21172996.7A patent/EP3889145B1/en active Active
- 2016-12-16 RS RS20240342A patent/RS65319B1/sr unknown
- 2016-12-16 KR KR1020187018717A patent/KR102787063B1/ko active Active
- 2016-12-16 EP EP21172998.3A patent/EP3889146A1/en active Pending
- 2016-12-16 MX MX2018006637A patent/MX385424B/es unknown
- 2016-12-16 CN CN201680081793.1A patent/CN108699032B/zh active Active
- 2016-12-16 PT PT211729967T patent/PT3889145T/pt unknown
- 2016-12-16 HR HRP20240355TT patent/HRP20240355T1/hr unknown
- 2016-12-16 KR KR1020257009400A patent/KR20250043596A/ko active Pending
- 2016-12-16 HU HUE21172996A patent/HUE066591T2/hu unknown
- 2016-12-16 SG SG10202001146PA patent/SG10202001146PA/en unknown
- 2016-12-16 DK DK21172996.7T patent/DK3889145T3/da active
- 2016-12-16 WO PCT/US2016/067112 patent/WO2017106607A1/en not_active Ceased
- 2016-12-16 CA CA3005766A patent/CA3005766A1/en active Pending
- 2016-12-16 AU AU2016371014A patent/AU2016371014B2/en active Active
- 2016-12-16 FI FIEP21172996.7T patent/FI3889145T3/fi active
- 2016-12-16 SM SM20240141T patent/SMT202400141T1/it unknown
- 2016-12-16 PL PL21172996.7T patent/PL3889145T3/pl unknown
- 2016-12-16 ES ES16840344T patent/ES2883285T3/es active Active
- 2016-12-16 NZ NZ742476A patent/NZ742476A/en unknown
- 2016-12-16 MX MX2021006804A patent/MX2021006804A/es unknown
- 2016-12-16 ES ES21172996T patent/ES2981114T3/es active Active
- 2016-12-16 EP EP16840344.2A patent/EP3390389B1/en active Active
- 2016-12-16 LT LTEP21172996.7T patent/LT3889145T/lt unknown
- 2016-12-16 SG SG11201804170RA patent/SG11201804170RA/en unknown
- 2016-12-16 MY MYPI2023001174A patent/MY210123A/en unknown
- 2016-12-16 UA UAA201807881A patent/UA124802C2/uk unknown
- 2016-12-16 MY MYPI2018702111A patent/MY196319A/en unknown
- 2016-12-16 CN CN202110952016.2A patent/CN113603675A/zh active Pending
- 2016-12-16 SI SI201631813T patent/SI3889145T1/sl unknown
- 2016-12-16 US US15/381,406 patent/US10399957B2/en active Active
- 2016-12-16 JP JP2018531479A patent/JP6882299B2/ja active Active
- 2016-12-19 TW TW110137731A patent/TWI804003B/zh active
- 2016-12-19 TW TW112116054A patent/TWI886474B/zh active
- 2016-12-19 TW TW105142060A patent/TWI736566B/zh active
-
2018
- 2018-05-17 PH PH12018501068A patent/PH12018501068A1/en unknown
- 2018-05-21 ZA ZA2018/03367A patent/ZA201803367B/en unknown
- 2018-05-31 IL IL279751A patent/IL279751B/en active IP Right Grant
- 2018-05-31 IL IL259751A patent/IL259751B/en active IP Right Grant
- 2018-06-15 CL CL2018001624A patent/CL2018001624A1/es unknown
-
2019
- 2019-07-10 US US16/507,870 patent/US10544122B2/en active Active
- 2019-11-26 US US16/696,503 patent/US10696649B2/en active Active
-
2020
- 2020-04-28 US US15/929,348 patent/US10947213B1/en active Active
- 2020-12-19 US US17/128,021 patent/US11629134B2/en active Active
- 2020-12-24 IL IL279752A patent/IL279752B2/en unknown
- 2020-12-24 IL IL279751A patent/IL279751A/en active IP Right Grant
-
2021
- 2021-02-10 JP JP2021019843A patent/JP7317878B2/ja active Active
- 2021-08-17 AU AU2021218041A patent/AU2021218041B2/en active Active
-
2023
- 2023-03-06 US US18/179,211 patent/US20230303514A1/en not_active Abandoned
- 2023-07-19 JP JP2023117597A patent/JP2023126574A/ja active Pending
- 2023-12-18 AU AU2023285714A patent/AU2023285714A1/en not_active Abandoned
-
2024
- 2024-10-23 US US18/923,917 patent/US20250059157A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018537501A5 (OSRAM) | ||
| JP2019527718A5 (OSRAM) | ||
| JP2020537671A5 (OSRAM) | ||
| HRP20200179T1 (hr) | Spojevi heteroarila kao inhibitori irak i njihova uporaba | |
| RU2019105719A (ru) | Антагонисты tlr7/8 и их применение | |
| HRP20240355T1 (hr) | 8-cijano-5-piperidino-kinolini kao tlr7/8 antagonisti i njihova upotreba u liječenju imunoloških poremećaja | |
| TWI776994B (zh) | 經碸吡啶烷基醯胺取代之雜芳基化合物 | |
| RU2020123151A (ru) | Антагонисты tlr7/8 и их применение | |
| RU2020115596A (ru) | ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ TBK/IKKε И ИХ ПРИМЕНЕНИЯ | |
| JP2017524733A5 (OSRAM) | ||
| JP2017530959A5 (OSRAM) | ||
| JP2015518903A5 (OSRAM) | ||
| FI3788044T3 (fi) | RIP1:tä estäviä yhdisteitä ja menetelmiä niiden valmistamiseksi ja käyttämiseksi | |
| RU2017101829A (ru) | Пиразоловые соединения в качестве модуляторов fshr и пути их применения | |
| JP2017538689A5 (OSRAM) | ||
| JP2017509586A5 (OSRAM) | ||
| JP2018536634A5 (OSRAM) | ||
| RU2019131017A (ru) | Соединения гетероарила в качестве ингибиторов btk и их применение | |
| JP2014533281A5 (OSRAM) | ||
| JP2020517611A5 (OSRAM) | ||
| JP2018538248A5 (OSRAM) | ||
| RU2018120242A (ru) | Хинолиновые соединения, способы их получения и их применения в качестве лекарственного средства, ингибирующего транспортер уратов | |
| JP2017514910A5 (OSRAM) | ||
| JP2017502092A5 (OSRAM) | ||
| HRP20171763T1 (hr) | Derivati piridin-4-ila |